CD8A and neoplasm: After treatment, on day 7, 14, and 21, both the OVV-00 and OVV-01 treatment groups showed an increase in hCD3+ T cells, hCD3+CD8+ T cells, and hCD3+CD4+ T cells in peripheral blood and tumor TILs over time.